By acquiring OHSU's MolecularMD, the clinical research organization ICON, based in Dublin, Ireland, has expanded its laboratory offering in molecular diagnostic testing and brings expanded testing platforms.
Pacific Northwest National Laboratory and OHSU today announced a joint collaboration to improve patient care by focusing research on highly complex sets of biomedical data, and the tools to interpret them.
The Office of Cancer Clinical Proteomics Research (OCCPR) at the National Cancer Institute (NCI) announced the institutes that will comprise the Proteogenomic Translational Research Centers, a group created to collaborate with NCI-sponsored clinical trials.
Today the OHSU Knight Cancer Institute announced that internationally renowned bioengineering and technology expert Mike Heller, Ph.D., will join the institute’s Cancer Early Detection Advanced Research Center, or CEDAR, to lead its technology efforts.
A study of more than 500 cancer survivors found that many years after completing treatment, nearly half of women cancer survivors continued to experience chemotherapy-induced peripheral neuropathy, CIPN.
The National Cancer Institute has awarded a research team at the OHSU Knight Cancer Institute $9.2 million over five years to serve as a Research Center in the NCI’s Cancer Systems Biology Consortium, or CSBC.
May is Melanoma Awareness Month, and the OHSU Knight Cancer Institute will again hold the “War on Skin Cancer Event” Saturday, May 20, from 9 a.m. to 2 p.m., to educate the community about sun safety and skin cancer risk factors.
Kerri Winters-Stone, Ph.D., researches the use of physical activity to prevent and manage chronic disease. Her studies have shown that cancer survivors can benefit from exercise that reverses treatment-related side effects and symptoms.
Stephen Lloyd's recent research, published in the Proceedings of the National Academy of Sciences, drew upon his expertise as a cancer biologist and focused on a global health problem affecting hundreds of thousands of individuals in Southeast Asia and Sub-Saharan Africa, where a specific class of toxic compounds, called aflatoxins, are commonly found in food sources.
There’s an urgency in Anupriya Agarwal’s voice when she talks about her acute myeloid leukemia research: “We need to do something beyond what we’ve already done,” she said. “The treatment hasn’t changed in decades, and that can’t be our only answer.”
Vinay Prasad, M.D., M.P.H., has been awarded a $2 million grant to support an effort to uncover treatments and tests that are contradicted by reliable evidence. The three-year project calls for sharing the findings via a public website and developing teaching modules that can be incorporated into medical school or residency curricula.
The New England Journal of Medicine published results from a nearly 11-year follow-up study, that showed an estimated overall survival rate of 83.3 percent. According to the National Cancer Institute, prior to Gleevec’s 2001 FDA approval, fewer than 1 in 3 CML patients survived five years past diagnosis.
The OHSU Knight Cancer Institute and Legacy Health have signed business agreements with The Vancouver Clinic, or TVC, to expand their network of integrated adult cancer care clinics to southwest Washington. The agreement is the latest addition to the OHSU Knight-Legacy Health Cancer Collaborative, established in 2013.
Research published today in the journal Oncotarget, sought to better understand one “typo” in a standard leukemia assay, or test. While studying cancer biology and completing his doctorate at the OHSU Knight Cancer Institute, Kevin Watanabe-Smith, Ph.D., encountered a new problem: an issue with the model system itself.
Commenting on recent research findings from a team at Stanford University, Sancy Leachman, M.D., Ph.D., director of the OHSU Knight Cancer Institute’s Melanoma Research Program and chair of the Department of Dermatology in the OHSU School of Medicine, co-authored a Nature News and Views perspective that heralded artificial intelligence, or AI, an important step in the “final frontier” in cancer diagnosis.
Suse Skinner, 70, is fighting her second battle with cancer. In 2005 she was diagnosed with breast cancer, then in August 2016 she was admitted to OHSU for her first induction chemotherapy session for acute myeloid leukemia, where she underwent 24/7 chemotherapy for six days followed by six weeks of recovery.
An OHSU and Oregon State University study finds aspirin may slow the spread of some types of colon and pancreatic cancer cells, Their findings are published in the American Journal of Physiology—Cell Physiology.
Conversations centered on health care are increasingly taking place on social media. For example, doctors, patients, advocates, the FDA and members of the pharmaceutical industry frequently interact on Twitter, discussing new drugs and devices.
Recognizing a critical need to improve national vaccination rates for human papillomavirus, or HPV, the OHSU Knight Cancer Institute has united with all 69 National Cancer Institute-designated cancer centers in issuing a joint statement in support of recently revised recommendations from the Centers for Disease Control and Prevention.
OHSU research published in the Journal of Clinical Oncology shows that patients with lung cancer who have symptoms of depression have overall lower survival rates than those without depression symptoms.
As we age, as many as 10 to 30 percent of us spontaneously carry mutations in our blood cells that put us at risk for blood cancers and heart disease. Researchers at OHSU are leading a unique study for women aged 65 and older called WEAR, or Women.